TScan Therapeutics, Inc.
NASDAQ:TCRXBiotechnology
+$0.02 today
- Market cap
- $50.37M
- Beta
- 1.03
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$0.96
Volume 0.00M
Average 0.81M
TCRX Other Stockholders Equity
Equity items not reported separately, such as additional paid-in capital or treasury stock.
TScan Therapeutics, Inc.NASDAQ: TCRX
Other Stockholders Equity · Q1 FY2026 · quarter ended Mar 2026
Other stockholders equity remains negative
Q1 FY2026 other stockholders equity was $0, compared with $0 a year earlier.
Context
- Other stockholders equity amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Other stockholders equity increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Stockholders Equity history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Other Stockholders Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Stockholders Equity vs competitors
How TCRX compares with its peers on the latest reported figures
- TCRX's Mar 2026 other stockholders equity of $0 is the highest of the 10 companies compared; the peer median is $0.
- Other stockholders equity amounts to 0.0% of total assets for TCRX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $0 | — | — | 0.0% |
| Apr 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding TCRX) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for TCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 161.41M | 120.03M | 133.36M | 178.69M | 152.41M |
| Short-term Investments | 0 | 0 | 58.69M | 111.42M | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 4.25M | 4.1M | 2.19M | 2.61M | 4.8M |
| Total Current Assets | 165.65M | 124.13M | 194.24M | 292.72M | 157.21M |
| Property, Plant & Equipment (Net) | 17.26M | 69.2M | 71.23M | 71.6M | 66.45M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 5.2M | 5.04M | 0 | 0 | 5.03M |
| Tax Assets | 0 | 0 | 0 | 0 | 15.78M |
| Other Non-current Assets | 5.2M | 725K | 6.68M | 6.8M | (15.67M) |
| Total Non-current Assets | 22.45M | 74.96M | 77.91M | 78.4M | 71.58M |
| Total Assets | 188.11M | 199.09M | 272.15M | 371.12M | 228.79M |
| Account Payables | 1.77M | 2.91M | 2.37M | 4.28M | 1.24M |
| Short-term Debt | 1.65M | 3.68M | 3.35M | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 11.41M | 3.87M | 10.14M | 11.7M | 2.62M |
| Other Current Liabilities | 3.92M | 2.48M | 5.9M | 6.92M | 4.34M |
| Total Current Liabilities | 21.34M | 17.31M | 29.82M | 35.96M | 18.7M |
| Long-term Debt | 0 | 29.29M | 26.7M | 32.07M | 32.53M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 1.5M | 0 | 5.62M | 1.25M | 0 |
| Other Non-current Liabilities | 97K | 49K | (1) | 135K | 0 |
| Total Non-current Liabilities | 5.99M | 82.35M | 91.46M | 94.19M | 86.97M |
| Total Liabilities | 27.33M | 99.66M | 121.28M | 130.15M | 105.67M |
| Common Stock | 3K | 3K | 5K | 6K | 5K |
| Retained Earnings | (92.16M) | (158.38M) | (247.6M) | (375.1M) | (504.86M) |
| Accumulated OCI | 0 | 0 | 0 | 51K | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 160.78M | 99.43M | 150.87M | 240.97M | 123.12M |
| Total Debt | 6.04M | 85.98M | 92.43M | 97.38M | 94.14M |
| Net Debt | (155.36M) | (34.04M) | (40.93M) | (81.31M) | (58.27M) |
TScan Therapeutics, Inc.
NASDAQ:TCRX
Intrinsic Alpha fair value
Locked
Current Price
$0.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.